A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
about
A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.
@en
A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.
@nl
type
label
A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.
@en
A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.
@nl
prefLabel
A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.
@en
A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.
@nl
P2093
P2860
P921
P356
P1433
P1476
A phase II trial of 1st-line m ...... ng RAS mutation: JACCRO CC-11.
@en
P2093
Akinori Takagane
Akitaka Makiyama
Hironaga Satake
Hiroshi Nakayama
Kazuma Kobayashi
Manabu Shiozawa
Masahiro Gotoh
Masahiro Takeuchi
Masahito Kotaka
Masashi Fujii
P2860
P304
18811-18820
P356
10.18632/ONCOTARGET.24702
P407
P577
2018-04-10T00:00:00Z